SCHEMBL3018474

SCHEMBL3018474

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
TP53 P04637 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
CPT1A P50416 6/20 0.37
CPT1B Q92523 5/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTR7 P34969 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA1D P25100 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007820 0.96 ALDH1A1 (0.41) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3014929 0.96 MAPK1 (0.39) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3018358 0.96 HTT (0.39) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3007108 0.95 TDP1 (0.42) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3019226 0.95 TP53 (0.39) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3006331 0.94 TP53 (0.40) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3003698 0.94 CYP3A4 (0.39) MAPTTP53RAB9AKDM4EALDH1A1
SCHEMBL3012043 0.94 ALDH1A1 (0.42) MAPTTP53RAB9AALDH1A1POLB
SCHEMBL15671681 0.93 MAPT (0.38) MAPTTP53ALDH1A1LMNATSHR
SCHEMBL3010381 0.93 TP53 (0.40) MAPTTP53RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885TP53 2880/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.